We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Will FDA’s Pandemic Regulatory Flexibility Continue Afterward?
Will FDA’s Pandemic Regulatory Flexibility Continue Afterward?
The COVID-19 pandemic has brought about an “explosion” of interest in consumer diagnostics, but it remains to be seen if the regulatory flexibility the FDA has shown toward those products will continue beyond the public health emergency, a leading healthcare industry attorney says.